These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16341176)

  • 21. Monthly risedronate (Actonel) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2008 Sep; 50(1294):69-70. PubMed ID: 18772843
    [No Abstract]   [Full Text] [Related]  

  • 22. Bisphosphonates for osteoporosis.
    Favus MJ
    N Engl J Med; 2010 Nov; 363(21):2027-35. PubMed ID: 21083387
    [No Abstract]   [Full Text] [Related]  

  • 23. Immediate loading in mandible full-arch: pilot study in patients with osteoporosis in bisphosphonate therapy.
    Leonida A; Vescovi P; Baldoni M; Rossi G; Lauritano D
    J Oral Implantol; 2012 Feb; 38(1):85-94. PubMed ID: 20553153
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of osteoporosis in an active female patient?].
    Fassbender WJ
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2416. PubMed ID: 18988136
    [No Abstract]   [Full Text] [Related]  

  • 25. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
    [No Abstract]   [Full Text] [Related]  

  • 27. [Oral osteoporosis: a review and its dental implications].
    Inagaki K; Kurosu Y; Sakano M; Yamamoto G; Kikuchi T; Noguchi T; Yano H; Izawa H; Hachiya Y
    Clin Calcium; 2007 Feb; 17(2):157-63. PubMed ID: 17272871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence with bisphosphonate therapy in older people.
    Melo M; Qiu F; Sykora K; Juurlink D; Laupacis A; Mamdani M
    J Am Geriatr Soc; 2006 Jun; 54(6):1015-6. PubMed ID: 16776810
    [No Abstract]   [Full Text] [Related]  

  • 30. [Etidronate and calcitonin to PTH (1-84) in postmenopausal osteoporosis].
    Rodríguez Rodríguez LP
    An R Acad Nac Med (Madr); 2011; 128(1):169-91; discussion 191-8. PubMed ID: 23350342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates and glucocorticoids: effects on bone quality.
    Lems WF
    Arthritis Rheum; 2007 Nov; 56(11):3518-22. PubMed ID: 17968935
    [No Abstract]   [Full Text] [Related]  

  • 33. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease.
    Arase Y; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Ikeda K; Kumada H
    J Med Virol; 2008 Jul; 80(7):1302-7. PubMed ID: 18461628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
    Yamaguchi K; Oizumi T; Funayama H; Kawamura H; Sugawara S; Endo Y
    J Oral Maxillofac Surg; 2010 Apr; 68(4):889-97. PubMed ID: 20056305
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PHARMAC responds on agents to prevent osteoporotic fractures.
    Metcalfe S; Wilkinson T; Rasiah D
    N Z Med J; 2006 Mar; 119(1230):U1895. PubMed ID: 16532056
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
    Ilter E; Karalok H; Tufekci EC; Batur O
    Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of Risedronate by biochemical bone markers in clinical practice.
    Bunyaratavej N
    J Med Assoc Thai; 2005 Oct; 88(suppl 5):S34-6. PubMed ID: 17500121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ibandronic acid IV: new formulation. Unconvincing evidence.
    Prescrire Int; 2008 Feb; 17(93):10. PubMed ID: 18354845
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.